Showing results (241-250 of 281) with videos related to
Sort By:
Pageof 29
Molecular Therapy. Nucleic Acids|June 26, 2020
Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 AxisYu-Shui Ma, Kai-Jian Chu, Chang-Chun Ling, et al.Ebiomedicine|April 28, 2019
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trialYi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, et al.Clinical & Translational Immunology|June 5, 2024
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Ji Chen, Jie Jiang, et al.Thoracic Cancer|April 8, 2022
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancersJia Tao Zhang, Song Dong, Li Yan Ji, et al.Molecular Therapy. Nucleic Acids|November 16, 2022
Retraction Notice to: Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 AxisYu-Shui Ma, Kai-Jian Chu, Chang-Chun Ling, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLCMei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.Thoracic Cancer|September 7, 2021
High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancerHui-Bo Feng, Yu Chen, Zhi Xie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II StudyWen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.Oncoimmunology|April 11, 2024
Redox<sup>high</sup> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinomaXue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung AdenocarcinomaZhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.Pageof 29